Form 8-K · Current Report · Filed 2025-01-13
Revvity Announces Preliminary Q4 Results and Upcoming Presentation at J.P. Morgan Conference
Revvity, Inc. announced preliminary expectations for its Q4 2024 financial results, projecting approximately 5% reported revenue growth and 6% organic revenue growth, with total Q4 revenue expected to be around $730 million. The company also expects full-year 2024 adjusted earnings per share to meet or exceed prior guidance. Revvity's CEO, Dr. Prahlad Singh, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company will release its Q4 and full-year 2024 financial results on January 31, 2025, and will host a conference call to discuss these results.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-25-000003
- CIK
- 0000031791
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Market reaction
Close before filing
$113.88
Next session
+6.0%
Since filing
+28.8%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (2)
About Revvity Inc.
Revvity Inc. is a prominent company in the healthcare and biological sciences field, offering a comprehensive suite of solutions aimed at improving global health outcomes. The company's core focus lies in delivering innovative products and services that range from diagnostic tools to advanced analytical capabilities for life sciences research. Revvity serves a wide array of sectors including biotechnology, pharmaceuticals, and clinical diagnostics, providing essential tools and data analytics that aid in disease discovery, drug development, and health monitoring. The company's expertise in deploying cutting-edge technologies further reinforces its position as a critical enabler of scientific research and innovation. With its global reach and commitment to enhancing healthcare delivery, Revvity Inc. plays a pivotal role in advancing the capabilities of medical and scientific communities worldwide, driving progress in critical areas such as personalized medicine and preventive healthcare.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.